N²-(trans-4-aminocyclohexyl)-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N²-(trans-4-aminocyclohexyl)-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
• 化学式: C₁₆H₂₃N₇
• 分子量: 313.406
• InChiKey: AONLJIQJHRPQBZ-HAQNSBGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  104.54
• 氢给体数：
  4.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  3-氨基-5-环丙基-1H-吡唑 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二甲基亚砜 、 正丁醇 为溶剂， 反应 34.0h， 生成 N²-(trans-4-aminocyclohexyl)-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors

  摘要：

  The p21-activated kinases (PAKs) play important roles in cytoskeletal organization, cellular morphogenesis, and survival and have generated significant attention as potential therapeutic targets for cancer. Following a high-throughput screen, we identified an aminopyrazole scaffold-based series that was optimized to yield group I selective PAK inhibitors. A structure-based design effort aimed at targeting the ribose pocket for both potency and selectivity led to much-improved group I vs II selectivity. Early lead compounds contained a basic primary amine, which was found to be a major metabolic soft spot with in vivo clearance proceeding predominantly via N-acetylation. We succeeded in identifying replacements with improved metabolic stability, leading to compounds with lower in vivo rodent clearance and excellent group I PAK selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00572

文献信息

• MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN
  申请人：Nalo Therapeutics

  公开号：US20210369710A1

  公开（公告）日：2021-12-02

  Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.
• Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors
  作者：James J. Crawford、Wendy Lee、Ignacio Aliagas、Simon Mathieu、Klaus P. Hoeflich、Wei Zhou、Weiru Wang、Lionel Rouge、Lesley Murray、Hank La、Ning Liu、Peter W. Fan、Jonathan Cheong、Christopher E. Heise、Sreemathy Ramaswamy、Robert Mintzer、Yanzhou Liu、Qi Chao、Joachim Rudolph

  DOI：10.1021/acs.jmedchem.5b00572

  日期：2015.6.25

  The p21-activated kinases (PAKs) play important roles in cytoskeletal organization, cellular morphogenesis, and survival and have generated significant attention as potential therapeutic targets for cancer. Following a high-throughput screen, we identified an aminopyrazole scaffold-based series that was optimized to yield group I selective PAK inhibitors. A structure-based design effort aimed at targeting the ribose pocket for both potency and selectivity led to much-improved group I vs II selectivity. Early lead compounds contained a basic primary amine, which was found to be a major metabolic soft spot with in vivo clearance proceeding predominantly via N-acetylation. We succeeded in identifying replacements with improved metabolic stability, leading to compounds with lower in vivo rodent clearance and excellent group I PAK selectivity.